The Cancer Letter

Inside information on cancer research and drug development

Vol.
36
No.
11
November 29, 2013Nov 29, 2013
Free
DOWNLOAD THE PDF

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response

FDA Grants Accelerated Approval to Imbruvica

Two Papers Evaluate CyberKnife Survival Rates and Tolerability

ANG1005 Demonstrates Activity In Patients with Brain Metastases

MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues

AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial

NCI CTEP Approved Trials For the Month of November

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account